XML 39 R27.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS, NET (Tables)

3 Months Ended

Mar. 31, 2016

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2016 and December 31, 2015:

		March 31, 2016
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent		$	31,951			$	(4,993	)		$	26,958				13.5
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			779,777				(60,579	)			719,198				16.75
Hormone therapy drug candidate patents (pending)			787,149				—				787,149				n/a
Non-amortizing intangible assets:
Multiple trademarks for vitamins/supplements			161,241				—				161,241				indefinite
Total		$	1,851,861			$	(157,315	)		$	1,694,546

		December 31, 2015
		Gross Carrying Amount				Accumulated Amortization				Net Amount				Weighted- Average Remaining Amortization Period (yrs.)
Amortizing intangible assets:
OPERA^®software patent		$	31,951			$	(4,493	)		$	27,458				13.75
Development costs of corporate website			91,743				(91,743	)			—				n/a
Approved hormone therapy drug candidate patents			705,752				(49,845	)			655,907				17
Hormone therapy drug candidate patents (pending)			774,165				—				774,165				n/a
Non-amortizing intangible assets:
Multiple trademarks for vitamins/supplements			157,721				—				157,721				indefinite
Total		$	1,761,332			$	(146,081	)		$	1,615,251

Schedule of estimated amortization expense

Estimated amortization expense for the next five years is as follows:

Year Ending December 31,			Estimated Amortization
2016 (9 months)			$	33,701
2017			$	44,934
2018			$	44,934
2019			$	44,934
2020			$	44,934